Association of single-nucleotide polymorphism 3 and c.553G>T of APOA5 with hypertriglyceridemia after treatment with highly active antiretroviral therapy containing protease inhibitors in hiv-infected individuals in Taiwan.
We investigated the relationship between hypertriglyceridemia and the single-nucleotide polymorphisms (SNPs) on APOA5 in human immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral therapy (HAART) in Taiwan. Receipt of protease inhibitor-based HAART, high baseline triglyceride levels, and carriage of APOA5 SNP3 or c.553G>T variants or APOA5 SNP1T/SNP2G/SNP3C/c.553T haplotype were statistically significantly associated with development of extreme hypertriglyceridemia (triglyceride level, >500 mg/dL).
Chang
Sui-Yuan
SY
Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan.
Ko
Wei-Shin
WS
Kao
Jau-Tsuen
JT
Chang
Lan-Yang
LY
Sun
Hsin-Yun
HY
Chen
Mao-Yuan
MY
Hsieh
Szu-Min
SM
Sheng
Wang-Huei
WH
Chang
Shu-Fang
SF
Liu
Wen-Chun
WC
Wu
Cheng-Hsin
CH
Hsu
Hui-Jen
HJ
Kao
Chuan-Liang
CL
Lee
Chun-Nan
CN
Hung
Chien-Ching
CC
Chang
Shan-Chwen
SC
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D000072040:Apolipoprotein A-V; D001054:Apolipoproteins A / Q000235:genetics*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006239:Haplotypes; D006801:Humans; D015228:Hypertriglyceridemia / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D017354:Point Mutation; D020641:Polymorphism, Single Nucleotide; D013624:Taiwan; D055815:Young Adult
C437704:APOA5 protein, human; D000072040:Apolipoprotein A-V; D001054:Apolipoproteins A; D017320:HIV Protease Inhibitors